Gastric Balloon vs GLP-1: Which Wins on Weight Loss, Durability, and Safety?

Should you get an intragastric (gastric) balloon or take a GLP-1 like Wegovy (semaglutide) or Zepbound (tirzepatide)? There is no head-to-head randomized trial, so this is a cross-trial comparison — but the shape of the answer is clear. A gastric balloon is a temporary, one-time device left in for about 6 months, delivering roughly 7–15% total body weight loss (TBWL) that peaks near ~11–13% and then partly reverses after removal^[1]. A GLP-1 is an ongoing medication delivering a larger, sustained-while-taking loss — about 14.9% with semaglutide^[3] and 20.9% with tirzepatide^[4]. The balloon also carries a documented FDA safety signal, including death reports^[6] that a GLP-1 does not require in the same form. The honest verdict: for most people a GLP-1 — or endoscopic sleeve gastroplasty (ESG) if you want a more durable procedure — is the stronger option, and the balloon's real niche is a short-term jump-start.

The honest verdict up front

• The GLP-1 wins on magnitude and durability for most people. Semaglutide (~14.9%^[3]) and tirzepatide (~20.9%^[4]) both beat the balloon's ~7–15%^[1] — and the drug's loss is sustained as long as you take it, while the balloon's ends at 6 months and commonly regains.
• The balloon wins on being one-and-done and drug-free. No weekly injection, no monthly prescription, no supply shortages — a single ~20-minute placement and a 6-month course. That is its genuine appeal.
• Safety framing differs in kind. The balloon carries an FDA safety signal — 18 death reports worldwide, gastric perforation, acute pancreatitis, and spontaneous hyperinflation^[6]. A GLP-1's common issues are gastrointestinal side effects that usually settle. This is a real point in the drug's favor.
• The metabolic benefits both exist. The balloon improves glucose, waist circumference, and blood pressure (diabetes-resolution OR ~1.4^[2]); GLP-1s have large cardiometabolic outcome trials behind them.
• If you want a durable procedure rather than a drug, look past the balloon to ESG. ESG (~13.6%^[5]) lasts years, not months — see ESG vs GLP-1.
• Bottom line: GLP-1 or ESG for durable results; balloon as a short-term jump-start for the right person — detailed below.

The core difference: a 6-month device vs an ongoing drug

Everything else follows from one structural fact. A gastric balloon (Orbera, ReShape, Obalon, or Spatz) is a soft silicone balloon placed in the stomach to take up space so you feel full sooner, left in for about 6 months, then endoscopically removed. Its weight loss peaks while the balloon is in and partly reverses after it comes out, because nothing about your anatomy or biology has been permanently changed^[1]. A GLP-1 is a weekly injection that suppresses appetite pharmacologically; its weight loss builds over roughly a year and is sustained as long as you keep taking it — and, like the balloon's, tends to reverse if you stop^[3][4]. So the real question is not just “which loses more weight,” but “do you want a time-limited procedure or an open-ended prescription?”

Head-to-head: the numbers, cross-trial

No trial has compared a balloon against a GLP-1 directly, so the table below stitches together each intervention's own pivotal evidence. Read it as directional, not as a contest — but the direction is unambiguous.

• Magnitude: a GLP-1 matches or beats the balloon even at the balloon's 6-month peak, and tirzepatide beats it clearly^[1][4].
• Durability: this is the balloon's core weakness. Its effect is capped at 6 months and regain is common; the drug's effect persists while taken^[3].
• Both clear the medical-society adoption bar for their category — the balloon meets the ASGE/ASMBS “PIVI” thresholds of at least 25% excess weight loss and at least 5% more TBWL than control^[1][7] — but clearing the bar is not the same as being the best option.

Where the balloon actually has an edge

The balloon is not a bad device — it is a mismatched one for the “durable weight loss” goal most people bring. Where it genuinely competes:

• One-and-done, drug-free. If the idea of a weekly injection indefinitely is a dealbreaker, a single 6-month device is a real alternative — no daily pills, no shortages, no ongoing prescription.
• A defined-period jump-start. For building early momentum, breaking a plateau, or losing weight ahead of another intervention, a 6-month course can kick-start change^[1].
• Fast, real metabolic improvement while in place. Glucose, waist circumference, and blood pressure all improved in the pooled data, with a diabetes-resolution odds ratio around 1.4^[2].
• For people who can't take or afford a GLP-1 long-term. A bounded, non-drug option can suit those for whom an open-ended prescription is not realistic.

Prefer a GLP-1? Top vetted providers

If you want a procedure, look at ESG before a balloon

Some people specifically want a procedure, not a lifelong drug — and that is a legitimate preference. But within the procedural options, the balloon is usually the wrong first stop. Endoscopic sleeve gastroplasty (ESG) is also incisionless and done through the mouth, yet it produced ~13.6% TBWL in the MERIT randomized trial and holds for years, not months^[5]. So the honest procedural ladder for most people is ESG over a balloon, with the balloon reserved for those who specifically want a shorter, lower-commitment, fully reversible course. Compare the procedures directly in ESG vs gastric sleeve and the full endoscopic options overview, and see the explainer on what a gastric balloon is for the device details.

How to choose

• Choose a GLP-1 if you want the largest, most sustained weight loss, you're willing to take an ongoing medication, and you want the lower-risk profile — this fits most people^[3][4].
• Choose ESG if you specifically want a durable, one-time procedure rather than a drug and are willing to pay out of pocket for a years-long result^[5].
• Choose a balloon if you want a short, defined, fully reversible, drug-free jump-start, you understand the effect ends at 6 months and regain is common, and you accept the FDA-reported risks^[1][6].
• Consider sequencing. A balloon as a jump-start followed by a GLP-1 or behavior program for maintenance is plausible — though not established in large trials — and mirrors how obesity is increasingly treated in stages.

What we still don't know

• No head-to-head balloon-vs-GLP-1 trial exists — every comparison here is cross-trial and directional.
• Real-world kept-off weight after balloon removal is under-characterized; the headline figures sit around a device that comes out at 6 months^[1].
• The best balloon-then-drug (or drug-then-procedure) sequence is unsettled and not validated in large trials.
• Newer and gas-filled balloon designs may carry a different risk profile than the liquid-filled devices behind most of the FDA safety reports^[6].

Bottom line

• A GLP-1 delivers more weight loss (~15–21%) that is sustained while taken^[3][4]; a balloon delivers ~7–15% that peaks at 6 months and partly reverses^[1].
• The balloon carries an FDA safety signal, including 18 death reports worldwide, that a GLP-1 does not require in the same form^[6].
• Both improve metabolic markers^[2], but the drug's durability and outcome evidence are stronger.
• For most people, a GLP-1 — or ESG for a durable procedure^[5] — is the stronger option. The balloon's honest niche is a short-term, drug-free jump-start.

Related research

• Gastric balloon: the full evidence — devices, weight loss, FDA safety, and cost in depth
• Endoscopic sleeve gastroplasty (ESG) — the durable incisionless alternative to a balloon
• ESG vs GLP-1 (semaglutide, tirzepatide) — procedure vs drug at a higher weight-loss tier
• Endoscopic weight-loss options — the full menu of bariatric endoscopy
• Bariatric surgery vs GLP-1s — the drug-vs-surgery comparison for larger, durable loss
• What is the safest form of weight-loss surgery? — procedural risk compared
• How much is weight-loss surgery? — where the balloon's cost fits
• Does insurance cover weight-loss surgery? — why the balloon is usually out of pocket

Important disclaimer. This article is educational and does not constitute medical advice. There is no head-to-head trial comparing a gastric balloon with a GLP-1; all comparisons here are cross-trial and directional. An intragastric balloon is an invasive device with real risks, including the FDA-reported deaths, gastric perforation, acute pancreatitis, and spontaneous hyperinflation described above; GLP-1 drugs have their own risks and side effects. Suitability for either must be assessed by a qualified physician based on your BMI, health, and goals. Cost figures are current US market ranges, not trial-derived. Do not start, stop, or change any treatment based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01, and the FDA safety facts were verified against fda.gov.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if a head-to-head balloon-vs-GLP-1 trial or a new FDA balloon safety communication is published.